Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Which Film Has the Incomparable Melodic Score? - 2Top 10 Arising Advances That Will Shape What's in store
- 3Watch South Korean startup Innospace attempt its 1st-ever orbital launch today
- 4NASA loses contact with its Maven spacecraft orbiting Mars for the past decade
- 5Minneapolis ICE shooting: Woman dies after federal agent opens fire on her vehicle amid immigration crackdown
- Gilead's new HIV prevention shot added to CVS's drug coverage lists, CEO says
- The Ascent of Rousing Pioneers Who Formed History
- The most exciting exoplanet discoveries of 2025
- Step by step instructions to Protect Your Senior Condo for Ideal Wellbeing and Solace
- Saturn's moon Titan may not have a buried ocean as long suspected, new study suggests
- Faulty glucose monitors linked to 7 deaths and more than 700 injuries, FDA warns
- Focus on Yourself: Wellbeing and Taking care of oneself Practices
- How to identify animal tracks, burrows and other signs of wildlife in your neighborhood
- Lift Your Style: Famous Hairdos for Ladies
